HC Wainwright Issues Optimistic Outlook for XOMA Earnings

XOMA Co. (NASDAQ:XOMA - Free Report) - Equities researchers at HC Wainwright raised their Q2 2025 earnings estimates for shares of XOMA in a report issued on Wednesday, May 28th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will post earnings per share of $0.06 for the quarter, up from their previous forecast of ($0.13). HC Wainwright has a "Buy" rating and a $104.00 price target on the stock. The consensus estimate for XOMA's current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for XOMA's Q3 2025 earnings at $0.03 EPS, Q4 2025 earnings at $0.39 EPS, FY2025 earnings at $0.62 EPS and FY2026 earnings at $1.16 EPS.

Several other equities analysts have also recently issued reports on the stock. Benchmark started coverage on shares of XOMA in a research note on Thursday, April 17th. They issued a "buy" rating and a $35.00 price objective on the stock. Wall Street Zen raised shares of XOMA from a "hold" rating to a "buy" rating in a research report on Friday.

XOMA Price Performance

Shares of XOMA traded down $0.87 during mid-day trading on Friday, hitting $24.63. The company's stock had a trading volume of 13,916 shares, compared to its average volume of 31,096. The firm has a 50-day moving average price of $22.93 and a 200 day moving average price of $25.06. The stock has a market capitalization of $294.75 million, a price-to-earnings ratio of -7.08 and a beta of 0.89. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52. XOMA has a fifty-two week low of $18.35 and a fifty-two week high of $35.00.

XOMA (NASDAQ:XOMA - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.32. The company had revenue of $15.91 million for the quarter, compared to analysts' expectations of $6.75 million. XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%.

Insider Transactions at XOMA

In related news, major shareholder Bvf Partners L. P/Il sold 392,723 shares of the business's stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $27.10, for a total transaction of $10,642,793.30. Following the transaction, the insider now directly owns 1,267,545 shares of the company's stock, valued at approximately $34,350,469.50. The trade was a 23.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CIO Bradley Sitko acquired 2,000 shares of the stock in a transaction that occurred on Monday, April 7th. The shares were bought at an average cost of $24.70 per share, for a total transaction of $49,400.00. Following the completion of the transaction, the executive now directly owns 5,045 shares of the company's stock, valued at $124,611.50. This represents a 65.68% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 29,312 shares of company stock valued at $735,061 over the last ninety days. Corporate insiders own 9.10% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC grew its position in XOMA by 1,063.8% during the first quarter. GAMMA Investing LLC now owns 1,734 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 1,585 shares in the last quarter. New York State Common Retirement Fund grew its position in XOMA by 51.2% during the fourth quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company's stock valued at $62,000 after purchasing an additional 800 shares in the last quarter. Wells Fargo & Company MN grew its position in XOMA by 38.0% during the fourth quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company's stock valued at $113,000 after purchasing an additional 1,183 shares in the last quarter. Deutsche Bank AG grew its position in XOMA by 5,087.9% during the first quarter. Deutsche Bank AG now owns 6,433 shares of the biotechnology company's stock valued at $128,000 after purchasing an additional 6,309 shares in the last quarter. Finally, Bank of America Corp DE grew its position in XOMA by 34.7% during the fourth quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company's stock valued at $205,000 after purchasing an additional 2,009 shares in the last quarter. 95.92% of the stock is owned by hedge funds and other institutional investors.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.